Global Tumor Radioimmunotherapy Market Growth (Status and Outlook) 2024-2030

Global Tumor Radioimmunotherapy Market Growth (Status and Outlook) 2024-2030

Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

The global Tumor Radioimmunotherapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Tumor Radioimmunotherapy Industry Forecast” looks at past sales and reviews total world Tumor Radioimmunotherapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor Radioimmunotherapy sales for 2023 through 2029. With Tumor Radioimmunotherapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Radioimmunotherapy industry.

This Insight Report provides a comprehensive analysis of the global Tumor Radioimmunotherapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tumor Radioimmunotherapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Radioimmunotherapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Radioimmunotherapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Radioimmunotherapy.

United States market for Tumor Radioimmunotherapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Tumor Radioimmunotherapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Tumor Radioimmunotherapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Tumor Radioimmunotherapy players cover Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Radioimmunotherapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Beta-emitting
Targeted Alpha Therapy

Segmentation by Application:
Solid Tumor
Non Hodgkin Lymphoma

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Beta-emitting
Targeted Alpha Therapy

Segmentation by Application:
Solid Tumor
Non Hodgkin Lymphoma

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.